Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Study of MYL-1701P versus Eylea in Diabetic Macular Edema
2017-004358-40Phase 3Completed
- Sponsor
- Mylan
- Start
- Jun 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of M710 in diabetic macular edema (DME), sponsored by Mylan. Started Jun 2018; status: completed.
02
Drugs
M710
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2017-004358-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004358-40.